Previous Chapter: References
Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.

Acronyms

ACCORD Action to Control Cardiovascular Risk in Diabetes

ACE inhibitor angiotensin-converting enzyme inhibitor

ADA American Dietetic Association

APOE apolipoprotein E

CAST Cardiac Arrhythmia Suppression Trial

CBER Center for Biologics Evaluation and Research

CD4 cells CD4+ T-lymphocytes

CDC Centers for Disease Control and Prevention

CDER Center for Drug Evaluation and Research

CDRH Center for Devices and Radiological Health

CEA carcinoembryonic antigen

CFSAN Center for Food Safety and Applied Nutrition

CHD coronary heart disease

CLIA Clinical Laboratory Improvement Amendments

CMS Centers for Medicare & Medicaid Services

COAG Clarification of Optimal Coagulation through Genetics

COPD chronic obstructive pulmonary disease

CRN Council for Responsible Nutrition

CRP C-reactive protein

CSPI Center for Science in the Public Interest

CVD cardiovascular disease

Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.

DDT drug development tools

DHA docosahexaenoic acid

EMEA European Medicines Agency

ESA erythropoiesis-stimulating agent

FAA Federal Aviation Administration

FDA Food and Drug Administration

FDAAA Food and Drug Administration Amendments Act

GAO Government Accountability Office

GI gastrointestinal

GMA Grocery Manufacturers Association

HDL high-density lipoprotein

HDL-C high-density lipoprotein cholesterol

HER2 human epidermal growth factor receptor 2

HHS Department of Health and Human Services

HIV human immunodeficiency virus

HRT hormone replacement therapy

IOM Institute of Medicine

IVD in vitro diagnostic

LDL low-density lipoprotein

LDL-C low-density lipoprotein cholesterol

MI myocardial infarction

MRI magnetic resonance imaging

NCI National Cancer Institute

NHANES National Health and Nutrition Examination Survey

NHLBI National Heart, Lung, and Blood Institute

NIH National Institutes of Health

NLEA Nutrition, Labeling, and Education Act

ODS Office of Dietary Supplements

PCI percutaneous coronary intervention

PET positron emission tomography

PML progressive multifocal leukoencephalopathy

PRO patient-reported outcomes

PSA prostate-specific antigen

Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.

PSTC Predictive Safety Testing Consortium

RT-PCR reverse-transcriptase polymerase chain reaction

SABRe Systems Approach to Biomarker Research in Cardiovascular Disease

SPECT single photon emission computed tomography

TLR target lesion revascularization

TSH thyroid-stimulating hormone

USDA United States Department of Agriculture

VRE vancomycin-resistant enterococci

Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.

This page intentionally left blank.

Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
Page 103
Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
Page 104
Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
Page 105
Suggested Citation: "Acronyms." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
Page 106
Next Chapter: Glossary
Subscribe to Emails from the National Academies
Stay up to date on activities, publications, and events by subscribing to email updates.